PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients  

作　　者：Mengyuan Gong Bo Zhang Xueni Wang Zeen Zhu Wei Li Liang Han Zheng Wu Qingyong Ma Zheng Wang Weikun Qian 

机构地区：[1]Department of Hepatobiliary Surgery,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China [2]Pancreatic Disease Center of Xi’an Jiaotong University,Xi’an 710061,China

出　　处：《Journal of Pancreatology》2024年第3期191-198,共8页胰腺病学杂志（英文）

基　　金：This study was funded by the National Natural Science Foundation of China(Grant Nos.82103117,82372895,82072702,and 82172853);This study was also supported by the Fundamental Research Funds for the Central Universities(Grant No.xtr052022008);the Natural Science Foundation of Shaanxi Province(Grant Nos.2022TD-43,2022PT-35,2020JM-367,2020JQ-510);the projects of Xi’an Municipal Bureau of Science and Technology(Grant No.20YXYJ0002(8)).

摘　　要：Background:Partly due to the limited effect of chemotherapy or other therapeutic strategies,which may be due to the insufficient knowledge of the tumor promotion markers and targets,pancreatic cancer(PC)holds the position of one of the most malignant tumors.This study aims to find a diagnosis/therapeutic molecule that can predict the prognosis of PC with different gene background.Methods:The Cancer Genome Atlas(TCGA)pancreatic duct adenocarcinoma(PAAD)–based single nucleotide polymorphisms and gene expression data were used to find the differentially expressed genes(DEGs)between KRAS/TP53 mutant samples and no gene mutation samples.Gene Set Enrichment Analysis(GSEA)-based Kyoto Encyclopedia of Genes and Genomes(KEGG)analysis and R-based gene oncology(GO)or immune cell invasion assay were used to explore the above DEGs involved pathways.The single-center PC cohort accompanied with next-generation sequence testing was used to verify the TCGA PAAD–based bioinformatic results.Results:First,we found PC patients who harbored KRAS and/or TP53 gene mutation have poor overall survival.Besides,the enrichment analysis showed that mutant KRAS/TP53 was correlated with PC tumor-promotion–related pathways and immune microenvironment.Next,we detected that prostate stem cell antigen(PSCA)was one of the most differential genes in KRAS/TP53 mutant PC tissues.Indeed,the bioinformatic analysis and our clinical data showed that PSCA was a biomarker of poor prognosis in PC.Conclusion:PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant PC patients.

关 键 词：Gene mutation Next generation sequence Pancreatic cancer Prostate stem cell antigen 

分 类 号：R735.9[医药卫生—肿瘤]